Nsclc Therapy Panel

What is NSCLC Therapy Panel test?

NSCLC Therapy Panel test is a combination of 3 key relevant genes for lung cancer which are EGFR mutation analysis, ALK by FISH and ROS1 by FISH.

• EGFR mutation detection test analyzes a patient's tumor tissue to identify genetic mutations in the Epidermal Growth Factor Receptor (EGFR) gene, primarily for non-small cell lung cancer (NSCLC). EGFR mutation detection test helps determine if a patient's cancer is susceptible to certain tyrosine kinase inhibitor (TKI) drugs, enabling personalized treatment plans and improved patient outcomes.
• ALK by FISH evaluates for ALK gene rearrangements, which are targetable with specific therapies (like alectinib, crizotinib, etc.)
• ROS1 gene rearrangement by FISH detects the split-apart signals in the ROS1 locus, indicating a ROS1 fusion in tumor cells—most commonly in lung adenocarcinoma—so patients can be considered for ROS1‑targeted tyrosine kinase inhibitors.

Why consider NSCLC Therapy Panel test?

The NSCLC therapy panel, which includes EGFR, ALK, and ROS1 testing, is a critical first step in managing non-small cell lung cancer (NSCLC)—especially adenocarcinoma. These genes are the most common actionable driver mutations, and identifying them enables targeted therapy, which is often more effective and less toxic than chemotherapy or immunotherapy.

• Detect Targetable Driver Mutations
• Guides First-Line Treatment
• Avoids Ineffective or Harmful Treatments

Who should get tested for NSCLC Therapy Panel test?

The NSCLC therapy panel test, which includes EGFR mutation, ALK rearrangement, and ROS1 rearrangement testing, should be performed in all patients with advanced non-squamous NSCLC, and in selected other cases. These biomarkers are critical for guiding targeted therapy decisions.

More Information about NSCLC Therapy Panel test

NSCLC stands for non-small cell lung cancer, the most common category of lung cancer that includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, and is managed with combinations of surgery, radiation, chemotherapy, targeted therapy, and immunotherapy based on stage and biomarkers. NSCLC (non-small cell lung cancer) is the most common type of lung cancer, making up about 80% of all lung cancer cases. It is a broad term for several types of epithelial lung cancers, with the main subtypes being adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.

Other names – NSCLC test, NSCLC Panel, NSCLC Therapy decision test